Cancers,
Год журнала:
2023,
Номер
15(3), С. 593 - 593
Опубликована: Янв. 18, 2023
The
possible
mechanisms
of
resistance
to
atezolizumab/bevacizumab
for
unresectable
HCC,
and
the
subsequent
response
these
therapies,
remain
underexplored.
sequential
changes
in
serum
growth
factors,
including
VEGF-A,
VEGF-C,
VEGF-D,
ANG-2,
FGF-19,
HGF,
EGF
during
HCC
were
evaluated
46
patients.
Patients
who
experienced
PD
after
CR,
PR,
or
SD
evaluated.
A
total
4,
9,
19,
14
patients
showed
SD,
PD,
respectively.
Of
32
with
disease
control,
28
atezolizumab/bevacizumab.
Baseline
factor
levels
similar
between
without
control
those
an
objective
response.
Growth
baseline
best
overall
points
(BOR)
that
FGF-19
significantly
increased
ANG2
decreased
at
BOR.
BOR
point
VEGF-D
compared
Summarily,
ANG-2
might
contribute
developing
be
target
molecules
salvage
therapies.
Cancers,
Год журнала:
2022,
Номер
14(22), С. 5525 - 5525
Опубликована: Ноя. 10, 2022
Lenvatinib
was
approved
in
2018
as
a
first-line
treatment
for
patients
with
unresectable
hepatocellular
carcinoma
(HCC).
This
systematic
review
and
meta-analysis
aimed
to
provide
the
most
updated
evidence
about
efficacy
safety
of
lenvatinib
HCC.
An
electronic
search
PubMed
database,
Web
Science,
Embase,
Cochrane
Library
undertaken
identify
all
relevant
studies
up
May
2022.
The
pooled
effect
sizes
were
calculated
based
on
random-effects
model.
One
phase
III
randomized
controlled
trial
23
retrospective
2438
eligible
analysis.
For
treated
treatment,
median
overall
survival
(OS),
progression-free
(PFS),
1-year
OS
rate,
PFS
objective
response
rate
(ORR),
disease
control
(DCR)
11.36
months,
6.68
56.0%,
27.0%,
36.0%
75.0%,
respectively.
showed
significantly
superior
compared
sorafenib
(HR
OS,
0.85
HR
PFS,
0.72;
OR
ORR,
4.25
DCR,
2.23).
current
study
demonstrates
that
can
better
tumor
responses
benefits
than
HCC,
comparable
incidence
adverse
events.
Clinical and Molecular Hepatology,
Год журнала:
2023,
Номер
29(2), С. 242 - 251
Опубликована: Март 21, 2023
Striking
advances
in
systemic
therapy
for
unresectable
advanced
hepatocellular
carcinoma
(HCC)
have
improved
the
average
prognosis
of
patients
with
HCC.
As
a
result,
guidelines
treatment
HCC
changed
significantly.
However,
various
issues
emerged
clinical
practice.
First,
there
is
no
established
biomarker
that
can
predict
response
to
therapy.
Second,
regimen
after
primary
therapy,
including
combined
immunotherapy.
Third,
intermediate-stage
These
points
make
current
ambiguous.
In
this
review,
we
present
Japanese
diagnosis
and
based
on
latest
evidence;
introduce
efforts
mainly
real-life
practice
update
these
guidelines;
our
perspectives
future
guidelines.
Current Oncology,
Год журнала:
2023,
Номер
30(10), С. 8774 - 8792
Опубликована: Сен. 26, 2023
Hepatocellular
carcinoma
(HCC)
represents
the
most
common
primary
liver
cancer
and
is
considered
a
major
global
health
problem
as
one
of
leading
causes
cancer-related
death
in
world.
Due
to
increase
life
expectancy
epidemiological
growth
specific
risk
factors,
such
metabolic
dysfunction-associated
steatotic
disease
(MASLD),
incidence
HCC
growing
globally,
mortality
rates
are
still
high.
Moreover,
patients
frequently
present
at
an
intermediate
or
advanced
tumor
stage,
when
curative
treatments,
surgical
resection,
transplantation
ablation
no
longer
applicable.
In
these
cases,
trans-arterial
chemoembolization
(TACE),
radioembolization
(TARE),
systemic
therapy
only
suitable
options
achieve
control.
The
multi-kinase
inhibitor
Sorafenib
has
been
treatment
available
for
unresectable
almost
decade,
but
last
couple
years
new
therapeutic
have
emerged.
Recent
advances
understanding
interactions
between
its
microenvironment,
especially
immune
escape,
led
advent
immunotherapy.
Currently,
first-line
represented
by
combination
checkpoint
(ICI)
Atezolizumab
plus
Bevacizumab,
anti-vascular
endothelial
factor
(VEGF)
monoclonal
antibody,
many
other
ICIs
investigated,
Nivolumab,
Pembrolizumab,
Durvalumab
Ipilimumab.
However,
second-
third-line
therapies,
correct
sequence
treatments
remains
open
not
addressed
studies.
This
explains
urge
find
that
can
improve
survival
quality
go
beyond
first
line
treatment.
aim
this
paper
offer
complete
overview
recent
innovations
locally
metastatic
HCC,
including
emerging
with
particular
focus
on
sequences.
we
will
provide
outlook
possible
future
approaches
who
progress
therapies.
Cancers,
Год журнала:
2023,
Номер
15(3), С. 593 - 593
Опубликована: Янв. 18, 2023
The
possible
mechanisms
of
resistance
to
atezolizumab/bevacizumab
for
unresectable
HCC,
and
the
subsequent
response
these
therapies,
remain
underexplored.
sequential
changes
in
serum
growth
factors,
including
VEGF-A,
VEGF-C,
VEGF-D,
ANG-2,
FGF-19,
HGF,
EGF
during
HCC
were
evaluated
46
patients.
Patients
who
experienced
PD
after
CR,
PR,
or
SD
evaluated.
A
total
4,
9,
19,
14
patients
showed
SD,
PD,
respectively.
Of
32
with
disease
control,
28
atezolizumab/bevacizumab.
Baseline
factor
levels
similar
between
without
control
those
an
objective
response.
Growth
baseline
best
overall
points
(BOR)
that
FGF-19
significantly
increased
ANG2
decreased
at
BOR.
BOR
point
VEGF-D
compared
Summarily,
ANG-2
might
contribute
developing
be
target
molecules
salvage
therapies.
